Novozymes 1 Q 2011: Outlook

摘要

Novozymes' full-year organic sales growth expectation and the expectation for growth in local currency (LCY) are maintained at 7-10% and 10-13% respectively. Based on exchange rates at 28 Apr 2011, and including the acquisition of EMD/Merck Crop BioScience, sales growth in DKR is now expected at 8-11%. Within the Enzyme Business, Household Care Enzymes are expected to be the strongest contributor to full-year sales growth. Feed enzyme sales are still expected to be a good relative growth contributor.